MuzaffarH.QazilbashMD

Oncology • Houston, TX

Hematologic Oncology

Professor of Medicine

Join to view full profile

Dr. Qazilbash is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Qazilbash's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
University of ConnecticutResidency, Internal Medicine, 1991 - 1992
Wright State UniversityResidency, Internal Medicine, 1989 - 1991
Dow University of Health SciencesClass of 1987

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TX State Medical License 2002 - 2026
AL State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
TN State Medical License 2023 - 2025
WA State Medical License 2023 - 2025
GA State Medical License 2023 - 2024
WV State Medical License 1999 - 2003
VA State Medical License 1994 - 2000
American Board of Internal Medicine Hematology
Join now to see all

Clinical Trials

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome Start of enrollment: 1999 Dec 01
Completed
Phase 1, Phase 2
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients Start of enrollment: 2006 Jun 01
Completed
Phase 1, Phase 2
FM 140 vs FM100 Study in Patients With Multiple Myeloma Start of enrollment: 2002 Jan 01
Completed
Phase 2
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients Start of enrollment: 2004 Mar 01
Completed
Phase 1, Phase 2
PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation Start of enrollment: 2008 Mar 01
Withdrawn
Phase 1
Lenalidomide and High-Dose Melphalan Start of enrollment: 2010 Mar 01
Completed
Phase 1, Phase 2
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant Start of enrollment: 2010 Jul 20
Terminated
Phase 2
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma Start of enrollment: 2011 Sep 30
Completed
Phase 3
Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant Start of enrollment: 2011 Aug 01
Completed
Phase 2
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant Start of enrollment: 2019 Apr 11
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients Start of enrollment: 2023 Aug 17
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas.
Jeremy Ramdial, Ruitao Lin, Peter F Thall, Benigno C Valdez, Chitra Hosing
Bone Marrow Transplantation. 2024-12-01
Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant.
Curtis Marcoux, Sarah Pasyar, Denái R Milton, Hina N Khan, Mark R Tanner
British Journal of Haematology. 2024-11-28
Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease.
Curtis M Marcoux, Amin M Alousi, Jin Im, Laquisa C Hill, Portia Smallbone
Bone Marrow Transplantation. 2024-11-01

Journal Articles

Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction Drugs
Krina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
Pilot Study Using Post-Transplant Cyclophosphamide (PTCy), Tacrolimus and Mycophenolate GVHD Prophylaxis for Older Patients Receiving 10/10 HLA-Matched Unrelated Donor...
Uday R Popat, Amin Alousi, Issa F Khouri, Muzaffar Qazilbash, Richard E Champlin, Partow Kebriaei, Simrit Parmar, Chitra Hosing, Nature

Abstracts/Posters

Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial
Muzaffar H. Qazilbash, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation
Muzaffar H. Qazilbash, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Re...
Muzaffar H. Qazilbash, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS
Muzaffar H. Qazilbash, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation
Muzaffar H. Qazilbash, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receivi...
Muzaffar H. Qazilbash, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics ...
Muzaffar H. Qazilbash, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression
Muzaffar H. Qazilbash, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)
Muzaffar H. Qazilbash, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma
Muzaffar H. Qazilbash, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Highlights of ASH 2024: Focus on Multiple MyelomaDecember 2024
ASH 2020: What’s New in Stem Cell Transplant and Cellular Therapy in Multiple Myeloma?December 2020

Press Mentions

Multiple Myeloma and Spine Cancer Survivor: ‘Always Think About a Second Opinion’September 23rd, 2024
Medical Laboratory Scientist Faces Her Own Multiple Myeloma DiagnosisJuly 15th, 2022
Immunotherapies Target Multiple MyelomaNovember 25th, 2020
Join now to see all